Sterling deal securitizes two data centres in Slough

International interest for German paper has grown

◆ Dutch lender's latest €2.5bn senior holdco follows Aussie domestic senior foray ◆ Comes a day after $1.5bn AT1 and before green RMBS ◆ Demand for senior unsecured assets is strong as ING clears big funding with limited, if any, new issue concession

◆ Issuer's first green benchmark in 2026 ◆ Blended premium estimated ◆ Central bank/official institution allocations 'notable and high' for green label

Bankers insist sustainability-linked loans are here to stay

◆ Demand sticky despite tight pricing ◆ Trade performing in secondary ◆ Tight senior/sub spread spotted

Only one of Canada's big five banks has yet to publicly support new defence bank initiative

Hyperscaler earnings could become a crucial date for issuance funding calendars

Cologix taps private ABS for latest trade

Chemical sector's growing uncompetitiveness a problem when it comes to attracting investment in the capital markets

Canada throwing full weight behind plan for new multilateral lender for defence funding

Second Canadian lender to declare official support for embryonic SSA issuer as government takes lead on establishing new entity

◆ Second ever bond for the issuer ◆ Deal marketed to both SSA and credit investors ◆ Offers potential for tightening on the back of southern European convergence trade

BSTDB has had a tricky time since Russia attacked Ukraine, both of which are shareholders

Commodities trader halves its stake for £132m after shares soar

◆ Deal follows NextEra’s euro hybrid debut last year ◆ Eight year tranche draws the larger book ◆ More Reverse Yankee issuance expected to follow

The familiar problem of inter-creditor opacity has also reappeared

'Hard to classify' Italian corporate trade being marketed to FIG and SSA accounts

Investors and bankers grapple with 24% fall in Bitcoin since deal was rated

Investment banking travel was a relentless grind, not gold card access to global glamour

Books were nearly three times the issue size

Anis Lahlou is chief investment officer at Aperture Investors in London. He believes that asset managers must change the way they charge fees to their investors, by only charging them for market-beating performance.

BioNTech, the German biopharmaceuticals company, is selling 5.5m American Depositary Receipts (ADRs) on the Nasdaq through a share sale and a rights issue. The company, which is working with Pfizer to develop a vaccine for Covid-19, is the latest issuer to hit the market in a wave of biotech ECM issuance — but buyers are being warned against being too eager, reports Sam Kerr.

The International Finance Facility for Immunisation (IFFIm) was set up in 2006 to provide funding to Gavi, the Vaccine Alliance, itself a public/private sector partnership, to expedite the vaccination of children in the poorest countries against endemic infectious diseases. Doris Herrera-Pol, IFFIm board member and former director of global capital markets at the World Bank, spoke to GlobalCapital about the role the capital markets can play in the development and deployment of a Covid-19 vaccine.